Condition: COVID-19 · Sponsor: Consorci Sanitari de Terrassa
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
This description comes directly from the study's public registry record.
Anna Puigdellivol, Ph.D · 34-93-5884555 · apuigdellivol@cst.cat
Always discuss trial participation with your own doctor first.
| Hospital de Terrassa | Terrassa, Barcelona, Spain | Recruiting |
| Hospital of Terrassa | Terrassa, Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05504057